Regeneron's Trevogrumab Shows Promise in Preserving Muscle Mass When Combined with Wegovy in Weight-Loss Study
Regeneron's experimental drug trevogrumab, when combined with Novo Nordisk's Wegovy (semaglutide), helped preserve up to 80% of lean muscle mass compared to semaglutide alone in a mid-stage clinical study.
Biocon Receives Indian Regulatory Approval for Generic Liraglutide, Expanding GLP-1 Diabetes Treatment Access
Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.
Regeneron Licenses Chinese GLP-1/GIP Dual Agonist in $2 Billion Obesity Deal with Hansoh Pharma
Regeneron acquired exclusive rights to HS-20094, a dual GLP-1/GIP receptor agonist from Hansoh Pharmaceuticals, for $80 million upfront and up to $1.93 billion in milestone payments.
Veru's Enobosarm Shows Improved Safety Profile in Combination with Wegovy for Muscle-Preserving Obesity Treatment
Veru's enobosarm combined with Wegovy demonstrated reduced gastrointestinal side effects compared to Wegovy alone in a 168-person Phase 2 trial.
MC2 Therapeutics Names Trine Ahlgreen as CEO to Drive Global Expansion of Psoriasis Treatment Wynzora
MC2 Therapeutics appointed Trine Ahlgreen as Chief Executive Officer to lead global commercial expansion of its psoriasis treatment Wynzora Cream and PAD Technology platform.
Prothena Discontinues Birtamimab Development After Phase 3 Failure in AL Amyloidosis
Prothena's Phase 3 AFFIRM-AL trial of birtamimab for AL amyloidosis failed to meet its primary endpoint of time to all-cause mortality (HR=0.915, p-value=0.7680).
Gene Editing Faces Uncertainty as CRISPR Companies Navigate Regulatory Challenges
The gene editing sector is experiencing significant uncertainty, as highlighted at the recent American Society of Cell and Gene Therapy (ASCGT) annual meeting where industry leaders discussed regulatory challenges.
Novo Nordisk CEO Steps Down After Eight Years as Company Faces Market Pressures
Novo Nordisk CEO Lars Fruergaard Jørgensen announced his resignation after eight years leading the company through significant growth in the obesity treatment market.
Tourmaline Bio's Heart Disease Antibody Shows Promise in Phase 2, But Shares Fall Amid Competition Concerns
Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down After Eight-Year Tenure
Novo Nordisk has announced that CEO Lars Fruergaard Jørgensen will step down following a mutual agreement with the board, ending his eight-year leadership during which the company established itself as a pioneer in obesity treatment.